News | April 07, 2025
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
The freshly infused capital will primarily be deployed towards expansion and research & development
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Experts urge early detection & better access to care
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Methenamine Hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections
Subscribe To Our Newsletter & Stay Updated
